Skip to content

The efficacy and safety of etrifel saqir in obese patients with placebo

Clinical trial of weight loss programs in obese patientswith majoneh etrifel saqir in comparison with placebo

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201104206237N1
Enrollment
60
Registered
2011-06-21
Start date
2011-06-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: Drug majoneh etrifel saqir composed of Phyllanthus emblica, Terminalia chebula ret, Terminaliacitrina roxb, Myrobalanus nigrae, Terminalia bellerica, a component in
Treatment - Drugs
Placebo
Intervention group: Drug majoneh etrifel saqir composed of Phyllanthus emblica, Terminalia chebula ret, Terminaliacitrina roxb, Myrobalanus nigrae, Terminalia bellerica, a component inside almond oil
Control group: Volunteers will take a teaspoon concoction of placebo twice a day for three months.

Sponsors

Shahed University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Having BMI more than 30; age between 16 to 60 years old;(Between50 to 60 with normal ECG) inform consent signed by the patient; those who can over the next three months five times refer for take drugs and laboratory examination and Waist circumference > 102 cm (men) or > 88 cm (women) Exclusion Criteria: Heavy Smoking(More than twenty cigarettes per daily); pregnancy; patients with coronary heart vascular disease; diabetes mellitus; patients with proven malignancy, asthma, chronic cough, chronic lung inflammatory and bowel disease, fever of unknown origin; patients with a history of chronic kidney and liver disease(Exception fatty liver and not including obesity, allergies, skin problems, or occasional GERD or IBS symptoms); obesity due to endocrine (hypothyroidism, uncontrolled disease) disease; genetic obesity syndrome; patients treated recently with sliming drugs; patients in the last three months, have been taken thin regimes; having psychological problems(psychiatric disorder (including recent diagnosis depression, bipolar disorder, and anxiety determined by self-report during screening .( diagnosis in last three month); alcohol consumption; persons with weight loss after surgery and receiving corticosteroid or Immunosuppressive medications

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Body Mass Index. Timepoint: Monthly. Method of measurement: Calculation of height and Weight.;Waist circumference. Timepoint: Monthly. Method of measurement: Metric.;Weight. Timepoint: Monthly. Method of measurement: Scale.;Volume hip circumference. Timepoint: Before intervention, 4weeks after intervention,8 weeks after intervention, 12 weeks after intervention. Method of measurement: Metric.

Secondary

MeasureTime frame
Fasting blood glucose. Timepoint: Before intervention, 12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Blood pressure. Timepoint: Monthly. Method of measurement: Blood pressure barometer.;Serum Triglycerid. Timepoint: Before intervention, 12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum low density lipoprotein level. Timepoint: Before intervention, 12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum High Density Lipo protein(HDL). Timepoint: Before intervention, 12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum Cholestrole. Timepoint: Before intervention, 12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Alanine transaminase. Timepoint: At the begining and 12th week. Method of measurement: Laboratory measurement method auto analyzer.;Aspartate aminotransferase. Timepoint: Before intervention,12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum Creatinin. Timepoint: Before intervention,12 weeks after intervention. Method of measurement: Laboratory measurement method auto analyzer.;Serum Alkaline Phosphatase. Timepoint: At the begining and 12th week. Method of measurement: Laboratory measurement method auto analyzer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hamid Kamali

Tradtional institue

h_kamali@razi.tums.ac.i; kamaliseyyedhamid@yahoo.com00982166482491; 00982188996212; 00982188220038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026